AU2016228806B2 - Method of purifying albumin-fusion proteins - Google Patents

Method of purifying albumin-fusion proteins Download PDF

Info

Publication number
AU2016228806B2
AU2016228806B2 AU2016228806A AU2016228806A AU2016228806B2 AU 2016228806 B2 AU2016228806 B2 AU 2016228806B2 AU 2016228806 A AU2016228806 A AU 2016228806A AU 2016228806 A AU2016228806 A AU 2016228806A AU 2016228806 B2 AU2016228806 B2 AU 2016228806B2
Authority
AU
Australia
Prior art keywords
sequence
comprises seq
loop comprises
seq
loop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016228806A
Other languages
English (en)
Other versions
AU2016228806A1 (en
Inventor
Mariko FONSECA
Alan Hunter
Yiming Li
Timothy PABST
Christopher Thompson
Liu TIE
Xiangyang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2016228806A1 publication Critical patent/AU2016228806A1/en
Application granted granted Critical
Publication of AU2016228806B2 publication Critical patent/AU2016228806B2/en
Priority to AU2021200423A priority Critical patent/AU2021200423B2/en
Priority to AU2023204271A priority patent/AU2023204271B2/en
Priority to AU2026201911A priority patent/AU2026201911A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016228806A 2015-03-12 2016-03-11 Method of purifying albumin-fusion proteins Active AU2016228806B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2021200423A AU2021200423B2 (en) 2015-03-12 2021-01-22 Method of purifying albumin-fusion proteins
AU2023204271A AU2023204271B2 (en) 2015-03-12 2023-07-03 Method of purifying albumin-fusion proteins
AU2026201911A AU2026201911A1 (en) 2015-03-12 2026-03-13 Method of purifying albumin-fusion proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562132198P 2015-03-12 2015-03-12
US62/132,198 2015-03-12
PCT/US2016/022003 WO2016145307A1 (en) 2015-03-12 2016-03-11 Method of purifying albumin-fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200423A Division AU2021200423B2 (en) 2015-03-12 2021-01-22 Method of purifying albumin-fusion proteins

Publications (2)

Publication Number Publication Date
AU2016228806A1 AU2016228806A1 (en) 2017-08-31
AU2016228806B2 true AU2016228806B2 (en) 2020-10-22

Family

ID=56878920

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2016228806A Active AU2016228806B2 (en) 2015-03-12 2016-03-11 Method of purifying albumin-fusion proteins
AU2021200423A Active AU2021200423B2 (en) 2015-03-12 2021-01-22 Method of purifying albumin-fusion proteins
AU2023204271A Active AU2023204271B2 (en) 2015-03-12 2023-07-03 Method of purifying albumin-fusion proteins
AU2026201911A Pending AU2026201911A1 (en) 2015-03-12 2026-03-13 Method of purifying albumin-fusion proteins

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2021200423A Active AU2021200423B2 (en) 2015-03-12 2021-01-22 Method of purifying albumin-fusion proteins
AU2023204271A Active AU2023204271B2 (en) 2015-03-12 2023-07-03 Method of purifying albumin-fusion proteins
AU2026201911A Pending AU2026201911A1 (en) 2015-03-12 2026-03-13 Method of purifying albumin-fusion proteins

Country Status (10)

Country Link
US (3) US10683340B2 (enExample)
EP (2) EP3268389B1 (enExample)
JP (3) JP6862348B2 (enExample)
KR (2) KR20170124592A (enExample)
CN (1) CN107428817B (enExample)
AU (4) AU2016228806B2 (enExample)
CA (2) CA3260163A1 (enExample)
ES (1) ES2839211T3 (enExample)
IL (1) IL253971B (enExample)
WO (1) WO2016145307A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753567A1 (en) 2011-10-11 2020-12-23 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds and methods of use thereof
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
EA202092778A1 (ru) 2018-05-16 2021-05-27 ЛИБ ТЕРАПЬЮТИКС, ЭлЭлСи Композиции, содержащие pcsk9-связывающие молекулы, и способы применения
CN113286806A (zh) * 2018-11-09 2021-08-20 尼欧派普制药有限两合公司 治疗压力、免疫反应和中风综合征的多肽
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN110295152A (zh) * 2019-07-29 2019-10-01 北京泓恩生物科技有限公司 一种重组产朊假丝酵母尿酸酶的纯化方法
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
JP2023532544A (ja) * 2020-07-01 2023-07-28 メディミューン，エルエルシー 生物学的製剤を精製するための洗浄剤及び方法
CN112062833A (zh) * 2020-10-09 2020-12-11 国药集团武汉血液制品有限公司 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法
CN115677848A (zh) * 2022-10-24 2023-02-03 通化安睿特生物制药股份有限公司 一种制备高纯度高稳定性蛋白质的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149873A1 (en) * 2009-05-07 2012-06-14 Novozymes Biopharma Dk A/S Method for purifying albumin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
CA2079802C (en) 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
NZ511699A (en) 1998-12-02 2003-02-28 Phylos Inc DNA-protein fusions and uses thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1196637T3 (da) 1999-07-27 2007-07-30 Adnexus Therapeutics Inc Peptidacceptor-ligeringsmetoder
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
AU2002310502A1 (en) 2001-06-21 2003-01-08 Phylos, Inc. In vitro protein interaction detection systems
KR100524872B1 (ko) * 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
CA2572917C (en) 2004-07-06 2012-04-03 Bioren Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
CN101384623B (zh) 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
KR101610791B1 (ko) 2007-07-03 2016-04-11 다누타 크루셰프스카 알파­케토글루타레이트의 의약 용도
WO2009023184A2 (en) 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
KR20130020765A (ko) 2010-02-16 2013-02-28 메디뮨 엘엘씨 Ｈｓａ-관련 조성물 및 사용방법
WO2011130324A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
CN103379915A (zh) 2011-02-15 2013-10-30 米迪缪尼有限公司 Hsa相关组合物及使用方法
EP3753567A1 (en) 2011-10-11 2020-12-23 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds and methods of use thereof
MX2015005363A (es) * 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149873A1 (en) * 2009-05-07 2012-06-14 Novozymes Biopharma Dk A/S Method for purifying albumin

Also Published As

Publication number Publication date
CA3260163A1 (en) 2026-03-02
AU2023204271B2 (en) 2026-04-02
AU2016228806A1 (en) 2017-08-31
WO2016145307A1 (en) 2016-09-15
JP2018513124A (ja) 2018-05-24
CN107428817A (zh) 2017-12-01
IL253971A0 (en) 2017-10-31
EP3268389A1 (en) 2018-01-17
EP3268389A4 (en) 2018-08-08
US10683340B2 (en) 2020-06-16
JP6862348B2 (ja) 2021-04-21
AU2023204271A1 (en) 2023-07-27
JP7826243B2 (ja) 2026-03-09
US11548933B2 (en) 2023-01-10
AU2021200423A1 (en) 2021-02-25
AU2026201911A1 (en) 2026-04-02
KR20170124592A (ko) 2017-11-10
US20180105575A1 (en) 2018-04-19
US20230340074A1 (en) 2023-10-26
EP3842451A1 (en) 2021-06-30
ES2839211T3 (es) 2021-07-05
IL253971B (en) 2021-10-31
JP2023103368A (ja) 2023-07-26
EP3268389B1 (en) 2020-09-30
AU2021200423B2 (en) 2023-04-06
JP7320550B2 (ja) 2023-08-03
KR20240093725A (ko) 2024-06-24
JP2021105025A (ja) 2021-07-26
BR112017019401A2 (pt) 2018-05-02
CA2977675A1 (en) 2016-09-15
CN107428817B (zh) 2022-07-12
US20200407423A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
AU2023204271B2 (en) Method of purifying albumin-fusion proteins
JP7560507B2 (ja) ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
US9279014B2 (en) Methods for preparing an active TNFR-Fc fusion protein
CA3066893A1 (en) Cation exchange chromatography wash buffer
KR20210149779A (ko) Fc 영역 개변 항체의 정제 방법
JP2016519144A (ja) 最小限の単量体の分離を伴う組換えポリクローナル多量体の分離
JP2024539653A (ja) 生体液を精製するための組成物及び方法
KR20250148832A (ko) 알부민 융합 단백질의 정제방법
HK1245286B (en) Method of purifying albumin-fusion proteins
BR112017019401B1 (pt) Método de purificação de proteínas de fusão de albumina
BR122024023456A2 (pt) COMPOSIÇÃO COMPREENDENDO SUPORTES Tn3
RU2820588C2 (ru) Способы очистки гетеродимерных полиспецифических антител
HK40090436A (zh) Cd40l-特异性tn3-衍生的支架及其使用方法
HK40043765A (en) Cd40l-specific tn3-derived scaffolds and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)